Status:
COMPLETED
CD34 Selection of the Peripheral Blood Stem Cell Graft for Autologous Transplant
Lead Sponsor:
Stanford University
Conditions:
Breast Cancer
Eligibility:
All Genders
19-70 years
Phase:
PHASE1
PHASE2
Brief Summary
Evaluate the feasibility and safety of autologous transplantation of CD34+Thy-1+ hematopoietic stem cells afer high dose marrow ablative chemotherapy in patients with breast cancer.
Detailed Description
Selection of CD34+THY-1 Positive Cells From Peripheral Blood Cells Procured for Autologous Hematopoietic Support Following High Dose Treatment with BCNU, Cyclophosphamide \& Cisplatin for Stage IV Bre...
Eligibility Criteria
Inclusion
- stage IV breast cancer
- primary breast cancer does not express CD34+
- adequate organ function
- no evidence of active infection
Exclusion
- chemotherapy within 4 weeks
- CNS disease
Key Trial Info
Start Date :
September 1 1996
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2005
Estimated Enrollment :
99 Patients enrolled
Trial Details
Trial ID
NCT00186680
Start Date
September 1 1996
End Date
June 1 2005
Last Update
March 2 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Stanford University School of Medicine
Stanford, California, United States, 94305